Christopher Berger • UCSF Profiles

Christopher Berger, MD

Title(s)	Assistant Professor, Medicine
School	School of Medicine
Address	1001 Potrero Avenue, #5J4 San Francisco CA 94110
Phone	--
ORCID	0000-0002-0034-7544
vCard	Download vCard

Biography

Education and Training

University of Pittsburgh, Pittsburgh, PA USA	B.Phil	12/2006	International Health
Universitat Autònoma de Barcelona (UAB), Barcelona, Spain	Masters in Tropical Medicine and International Health	06/2007	Tropical Medicine and International Health
University of Pittsburgh, Pittsburgh, PA USA	MD	05/2012	Medicine
University of California San Francisco (UCSF), San Francisco, CA USA		06/2015	Internal Medicine Residency
University of California San Francisco (UCSF), San Francisco, CA USA		07/2019	Fellowship in Pulmonary and Critical Care Medicine

Overview

Christopher Berger, MD, MSIMT is an assistant professor in the UCSF Division of Pulmonary Critical Care Medicine, clinically based at Zuckerberg San Francisco General Hospital. His research focuses on improving tuberculosis screening, diagnosis, and treatment programs globally through the use of implementation science and human-centered design principles. He works with Dr. Adithya Cattamanchi on projects in the Philippines to improve the diagnostic and clinical tools used in MDR and XDR TB and in Uganda designing improved versions of the globally utilized “Directly Observed Therapy” toolkit. Christopher completed his undergraduate degree in international health at the University of Pittsburgh where he went on complete his MD. He received his master’s in tropical medicine and international health at the Universitat Autonoma de Barcelona in Barcelona, Spain. He completed his internal medicine residency and pulmonary/critical care medicine fellowship at UCSF. He is currently completing a masters in Clinical Research at UCSF.

Interests

Tuberculosis, Tuberculosis preventive therapy, Human-centered design, Implementation science, Digital adherence technologies

Websites

	UCSF Pulmonary, Critical Care, Allergy, and Sleep Medicine
	Center for Vulnerable Populations
	UCSF Center for Tuberculosis

Global Health Equity

Research

Research Activities and Funding

Digital adherence technologies to facilitate completion of short-course tuberculosis preventive therapy among people living with HIV
NIH K23HL156784Sep 8, 2021 - Aug 31, 2026
Role: Principal Investigator

Bibliographic

Publications

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.

Altmetrics Details

PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.

Comparison of 3 optimized delivery strategies for completion of isoniazid-rifapentine (3HP) for tuberculosis prevention among people living with HIV in Uganda: A single-center randomized trial. PLoS Med. 2024 Feb 20; 21(2):e1004356. Semitala FC, Kadota JL, Musinguzi A, Welishe F, Nakitende A, Akello L, Kunihira Tinka L, Nakimuli J, Ritar Kasidi J, Bishop O, Nakasendwa S, Baik Y, Patel D, Sammann A, Nahid P, Belknap R, Kamya MR, Handley MA, Phillips PP, Katahoire A, Berger CA, Kiwanuka N, Katamba A, Dowdy DW, Cattamanchi A. PMID: 38377166.

View in: PubMed Mentions: Fields:
Med Medicine (General)
Translation:Humans
Implementation, feasibility, and acceptability of 99DOTS-based supervision of treatment for drug-susceptible TB in Uganda. PLOS Digit Health. 2023 Jun; 2(6):e0000138. Kiwanuka N, Kityamuwesi A, Crowder R, Guzman K, Berger CA, Lamunu M, Namale C, Kunihira Tinka L, Nakate AS, Ggita J, Turimumahoro P, Babirye D, Oyuku D, Patel D, Sammann A, Turyahabwe S, Dowdy DW, Katamba A, Cattamanchi A. PMID: 37390077; PMCID: PMC10313004.

View in: PubMed Mentions: 1
Understanding patient-level costs of weekly isoniazid-rifapentine (3HP) among people living with HIV in Uganda. Int J Tuberc Lung Dis. 2023 06 01; 27(6):458-464. Sung J, Musinguzi A, Kadota JL, Baik Y, Nabunje J, Welishe F, Bishop O, Berger CA, Katahoire A, Nakitende A, Nakimuli J, Akello L, Kasidi JR, Kunihira Tinka L, Kamya MR, Sohn H, Kiwanuka N, Katamba A, Cattamanchi A, Dowdy DW, Semitala FC. PMID: 37231600; PMCID: PMC10316532.

View in: PubMed Mentions: Fields:
Pul Pulmonary Medicine
Translation:Humans
Barriers and Facilitators to Implementing a Digital Adherence Technology for Tuberculosis Treatment Supervision in Uganda: Qualitative Study. J Med Internet Res. 2023 05 30; 25:e38828. Leddy A, Ggita J, Berger CA, Kityamuwesi A, Sanyu AN, Tinka LK, Crowder R, Turyahabwe S, Katamba A, Cattamanchi A. PMID: 37252774; PMCID: PMC10265431.

View in: PubMed Mentions: 1 Fields:
Med Medical Informatics
Translation:Humans
Adherence trajectory as an on-treatment risk indicator among drug-resistant TB patients in the Philippines. PLoS One. 2022; 17(11):e0277078. Huddart S, Geocaniga-Gaviola DM, Crowder R, Lim AR, Lopez E, Valdez CL, Berger CA, Destura R, Kato-Maeda M, Cattamanchi A, Garfin AMC. PMID: 36346814; PMCID: PMC9642894.

View in: PubMed Mentions: Fields:
Med Medicine (General)Sci Science
Translation:Humans
Completion of isoniazid-rifapentine (3HP) for tuberculosis prevention among people living with HIV: Interim analysis of a hybrid type 3 effectiveness-implementation randomized trial. PLoS Med. 2021 12; 18(12):e1003875. Semitala FC, Kadota JL, Musinguzi A, Nabunje J, Welishe F, Nakitende A, Akello L, Bishop O, Patel D, Sammann A, Nahid P, Belknap R, Kamya MR, Handley MA, Phillips PPJ, Katahoire A, Berger CA, Kiwanuka N, Katamba A, Dowdy DW, Cattamanchi A. PMID: 34914696; PMCID: PMC8726462.

View in: PubMed Mentions: 3 Fields:
Med Medicine (General)
Translation:Humans
Acceptance and completion of rifapentine-based TB preventive therapy (3HP) among people living with HIV (PLHIV) in Kampala, Uganda-patient and health worker perspectives. Implement Sci Commun. 2021 Jun 30; 2(1):71. Semitala FC, Musinguzi A, Ssemata J, Welishe F, Nabunje J, Kadota JL, Berger CA, Katamba A, Kiwanuka N, Kamya MR, Dowdy D, Cattamanchi A, Katahoire AR. PMID: 34193311; PMCID: PMC8247167.

View in: PubMed Mentions: 7
Digital adherence technology for tuberculosis treatment supervision: A stepped-wedge cluster-randomized trial in Uganda. PLoS Med. 2021 05; 18(5):e1003628. Cattamanchi A, Crowder R, Kityamuwesi A, Kiwanuka N, Lamunu M, Namale C, Tinka LK, Nakate AS, Ggita J, Turimumahoro P, Babirye D, Oyuku D, Berger C, Tucker A, Patel D, Sammann A, Turyahabwe S, Dowdy D, Katamba A. PMID: 33956802; PMCID: PMC8136841.

View in: PubMed Mentions: 15 Fields:
Med Medicine (General)
Translation:Humans
Iterative Adaptation of a Tuberculosis Digital Medication Adherence Technology to Meet User Needs: Qualitative Study of Patients and Health Care Providers Using Human-Centered Design Methods. JMIR Form Res. 2020 Dec 08; 4(12):e19270. Patel D, Berger CA, Kityamuwesi A, Ggita J, Kunihira Tinka L, Turimumahoro P, Feler J, Chehab L, Chen AZ, Gupta N, Turyahabwe S, Katamba A, Cattamanchi A, Sammann A. PMID: 33289494; PMCID: PMC7755538.

View in: PubMed Mentions: 5
Study protocol and implementation details for a pragmatic, stepped-wedge cluster randomised trial of a digital adherence technology to facilitate tuberculosis treatment completion. BMJ Open. 2020 11 27; 10(11):e039895. Crowder R, Kityamuwesi A, Kiwanuka N, Lamunu M, Namale C, Tinka LK, Nakate AS, Ggita J, Turimumahoro P, Babirye D, Oyuku D, Berger CA, Tucker A, Patel D, Sammann A, Dowdy D, Stavia T, Cattamanchi A, Katamba A. PMID: 33247012; PMCID: PMC7703448.

View in: PubMed Mentions: 4 Fields:
Med Medicine (General)
Translation:Humans CTClinical Trials
Opportunities to improve digital adherence technologies and TB care using human-centered design. Int J Tuberc Lung Dis. 2020 10 01; 24(10):1112-1115. Berger C, Patel D, Kityamuwesi A, Ggita J, Tinka LK, Turimumahoro P, Neville K, Chehab L, Chen AZ, Gupta N, Turyahabwe S, Katamba A, Cattamanchi A, Sammann A. PMID: 33126949; PMCID: PMC9094398.

View in: PubMed Mentions: 5 Fields:
Pul Pulmonary Medicine
Translation:Humans
Variation in tuberculosis treatment outcomes and treatment supervision practices in Uganda. J Clin Tuberc Other Mycobact Dis. 2020 Dec; 21:100184. Berger CA, Kityamuwesi A, Crowder R, Lamunu M, Kunihira Tinka L, Ggita J, Sanyu Nakate A, Namale C, Oyuku D, Chen K, Turyahabwe S, Cattamanchi A, Katamba A. PMID: 33204851; PMCID: PMC7648165.

View in: PubMed Mentions: 4
Protocol for the 3HP Options Trial: a hybrid type 3 implementation-effectiveness randomized trial of delivery strategies for short-course tuberculosis preventive therapy among people living with HIV in Uganda. Implement Sci. 2020 08 12; 15(1):65. Kadota JL, Musinguzi A, Nabunje J, Welishe F, Ssemata JL, Bishop O, Berger CA, Patel D, Sammann A, Katahoire A, Nahid P, Belknap R, Phillips PPJ, Namusobya J, Kamya M, Handley MA, Kiwanuka N, Katamba A, Dowdy D, Semitala FC, Cattamanchi A. PMID: 32787925; PMCID: PMC7425004.

View in: PubMed Mentions: 6 Fields:
Hea Health Services Research
Translation:Humans CTClinical Trials
Summary for Clinicians: 2019 Clinical Practice Guideline Summary for the Treatment of Drug-Resistant Tuberculosis. Ann Am Thorac Soc. 2020 08; 17(8):911-917. Berger CA, Alipanah N, Kheir F, Ruminjo JK, Nahid P, Thomson C. PMID: 32464069.

View in: PubMed Mentions: 2 Fields:
Pul Pulmonary Medicine
Translation:Humans
Willingness to accept reimbursement for visits to an HIV clinic for tuberculosis preventive therapy. Int J Tuberc Lung Dis. 2020 07 01; 24(7):729-731. Kadota JL, Katamba A, Musinguzi A, Welishe F, Nabunje J, Ssemata JL, Berger CA, Kamya MR, Namusobya J, Semitala FC, Cattamanchi A, Dowdy DW. PMID: 32718409; PMCID: PMC7891860.

View in: PubMed Mentions: 5 Fields:
Pul Pulmonary Medicine
Translation:Humans
Management and Outcomes of Critically-III Patients with COVID-19 Pneumonia at a Safety-net Hospital in San Francisco, a Region with Early Public Health Interventions: A Case Series. medRxiv. 2020 May 29. Vanderburg S, Alipanah N, Crowder R, Yoon C, Wang R, Thakur N, Slown K, Shete PB, Rofael M, Metcalfe JZ, Merrifield C, Marquez C, Malcolm K, Lipnick M, Jain V, Gomez A, Burns G, Brown LB, Berger C, Auyeung V, Cattamanchi A, Hendrickson CM. PMID: 32511538; PMCID: PMC7273306.

View in: PubMed Mentions:
Presentation and outcome of suspected sepsis in a high-HIV burden, high antiretroviral coverage setting. Int J Infect Dis. 2020 Jul; 96:276-283. Chaka W, Berger C, Huo S, Robertson V, Tachiona C, Magwenzi M, Magombei T, Mpamhanga C, Katzenstein D, Metcalfe J. PMID: 32289564; PMCID: PMC8040698.

View in: PubMed Mentions: 2 Fields:
Com Communicable Diseases
Translation:Humans
Implementation science to improve the quality of tuberculosis diagnostic services in Uganda. J Clin Tuberc Other Mycobact Dis. 2020 Feb; 18:100136. Cattamanchi A, Berger CA, Shete PB, Turyahabwe S, Joloba M, Moore DA, Davis LJ, Katamba A. PMID: 31879703; PMCID: PMC6920311.

View in: PubMed Mentions: 12
Open-source point-of-care electronic medical records for use in resource-limited settings: systematic review and questionnaire surveys. BMJ Open. 2012; 2(4). Millard PS, Bru J, Berger CA. PMID: 22763661; PMCID: PMC3391372.

View in: PubMed Mentions: 13 Fields:
Med Medicine (General)